Improvement in health‐related quality of life and symptoms of anxiety and depression in patients with alopecia areata randomized to baricitinib or placebo: Results from two international randomized controlled trials
Abstract Background Alopecia areata (AA) is an autoimmune hair loss disorder associated with high rates of emotional and psychosocial distress. Baricitinib, an oral selective Janus kinase (JAK) 1 and JAK 2 inhibitor, was superior to placebo with respect to hair regrowth in two phase 3 trials involvi...
Salvato in:
| Autori principali: | , , , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Wiley
2024-03-01
|
| Serie: | JEADV Clinical Practice |
| Soggetti: | |
| Accesso online: | https://doi.org/10.1002/jvc2.269 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|